A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

Model scores of the 29,894 trials active now.

Model score 30% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: nsclccell lungsmall celllung cancernon small
  Phrases that lowered it: linecombinationarmdiseasespatients
• Sponsor's past termination rate: 46.2% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports with a death: 26.8% (raises risk) · Drug's FDA history
• Number of arms: 3 (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: 75 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 3 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 97.6% (raises risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Keywords listed: 0 (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer NCT02566993 · started 2016 · scored riskier than 84% of active trials completed
• Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy NCT00702975 · started 2008 · scored riskier than 80% of active trials completed
• Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors NCT01831089 · started 2013 · scored riskier than 69% of active trials completed
• Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors NCT01980667 · started 2014 · scored riskier than 29% of active trials completed
• Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer NCT01038752 · started 2010 · scored riskier than 93% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.